{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:03:51Z","timestamp":1793239431163,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine: X"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jvacx.2021.100107","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T11:53:11Z","timestamp":1624967591000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives"],"prefix":"10.1016","volume":"8","author":[{"given":"Kara M.","family":"Plotnikoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robine","family":"Donken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"LaMontagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Bettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Grennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Sarai","family":"Racey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Hybiske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Naus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina S.","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvacx.2021.100107_b0005","doi-asserted-by":"crossref","unstructured":"Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Radded LJ, et al. Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bulletin of the World Health Organization; 2019.","DOI":"10.2471\/BLT.18.228486"},{"key":"10.1016\/j.jvacx.2021.100107_b0010","unstructured":"Report on global sexually transmitted infection surveillance 2015. Geneva, Switzerland: World Health Organization; 2016."},{"key":"10.1016\/j.jvacx.2021.100107_b0015","unstructured":"Global health sector strategy on sexually transmitted infections 2016-2021 - Towards ending STIs. Geneva, Switzerland: World Health Organization; 2016."},{"issue":"1","key":"10.1016\/j.jvacx.2021.100107_b0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170773","article-title":"Costing of national STI program implementation for the global STI control strategy for the health sector, 2016\u20132021","volume":"12","author":"Korenromp","year":"2017","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.jvacx.2021.100107_b0025","first-page":"A156","article-title":"The economic burden of chlamydia and gonorrhea in Canada","volume":"87","author":"Smylie","year":"2011","journal-title":"Sexually Transmitted Infect"},{"key":"10.1016\/j.jvacx.2021.100107_b0030","unstructured":"Canadian guidelines on sexually transmitted infections. Ottawa, ON: Expert working group for the Canadian Guidelines on Sexually Transmitted Infections, Public Health Agency of Canada; 2008. Contract No.: HP40-1\/2010E-PDF."},{"key":"10.1016\/j.jvacx.2021.100107_b0035","unstructured":"Report on sexually transmitted infections in Canada: 2013-2014. Centre for Communicable Diseases and Infection Control, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada; 2017."},{"key":"10.1016\/j.jvacx.2021.100107_b0040","unstructured":"Global strategy for the prevention and control of sexually transmitted infections: 2006-2015. Geneva, Switzerland: World Health Organization; 2007."},{"issue":"2","key":"10.1016\/j.jvacx.2021.100107_b0045","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/jama.2012.205107","article-title":"Cephalosporin-resistant gonorrhea in North America","volume":"309","author":"Kirkcaldy","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jvacx.2021.100107_b0050","unstructured":"Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva, Switzerland: World Health Organization; 2012."},{"issue":"8","key":"10.1016\/j.jvacx.2021.100107_b0055","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1128\/CVI.00230-16","article-title":"Summary and recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) workshop \u201cGonorrhea vaccines: the way forward\u201d","volume":"23","author":"Wetzler","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.jvacx.2021.100107_b0060","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3201\/eid2106.141270","article-title":"Cost-effectiveness of Chlamydia vaccination programs for young women","volume":"21","author":"Owusu-Edusei","year":"2015","journal-title":"Emerg Infect Dis"},{"issue":"14","key":"10.1016\/j.jvacx.2021.100107_b0065","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.vaccine.2013.11.007","article-title":"The theoretical impact and cost-effectiveness of vaccines that protect against sexually transmitted infections and disease","volume":"32","author":"Garnett","year":"2014","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.jvacx.2021.100107_b0070","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/infdis\/jix004","article-title":"Therapeutic vaccine for genital herpes simplex virus-2 infection: findings from a randomized trial","volume":"215","author":"Bernstein","year":"2017","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.jvacx.2021.100107_b0075","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/infdis\/jiy415","article-title":"Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex virus-2, on viral shedding and lesions: Results of a randomized placebo-controlled trial","volume":"218","author":"Van Wagoner","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jvacx.2021.100107_b0080","doi-asserted-by":"crossref","unstructured":"Abraham S, Juel HB, Bang P, Cheeseman HM, B DR, Cole T, et al. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminum hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis 2019.","DOI":"10.1016\/S1473-3099(19)30279-8"},{"issue":"4","key":"10.1016\/j.jvacx.2021.100107_b0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1084\/jem.189.4.647","article-title":"Treponema pallidum major sheath protein homologue Tpr K is a target of opsonic antibody and the protective immune response","volume":"189","author":"Centurion-Lara","year":"1999","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.jvacx.2021.100107_b0090","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1365-2958.2011.07662.x","article-title":"TP0326, a Treponema pallidum \u03b2-barrel assembly machinery A (BamA) orthologue and rare outer membrane protein","volume":"80","author":"Desrosiers","year":"2011","journal-title":"Mol Microbiol"},{"issue":"1","key":"10.1016\/j.jvacx.2021.100107_b0095","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41598-017-01589-4","article-title":"Identification of Tp0751 (Pallilysin) as a Treponema pallidum vascular adhesin by heterologous expression in the Lyme disease spirochete","volume":"7","author":"Kao","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jvacx.2021.100107_b0100","doi-asserted-by":"crossref","first-page":"14273","DOI":"10.1038\/ncomms14273","article-title":"A defined syphilis vaccine candidate inhibits dissemination of Treponema pallidum subspecies pallidum","volume":"8","author":"Lithgow","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jvacx.2021.100107_b0105","unstructured":"De Serres G, Gari\u00e9py MC, Billard MN, Rouleau I. Initial dose of a multicomponent serogroup B Meningococcal vaccine in theSaguenay\u2013Lac-Saint-Jean region, Qu\u00e9bec, Canada: an interim safety surveillance report. Gouvernement du Qu\u00e9bec; 2014. Contract No.: ISBN: 978-2-550-71653-2."},{"issue":"10102","key":"10.1016\/j.jvacx.2021.100107_b0110","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0140-6736(17)31449-6","article-title":"Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study","volume":"390","author":"Petousis-Harris","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jvacx.2021.100107_b0115","article-title":"The serogroup B meningococcal vaccine Bexsero elicits antibodies to Neisseria gonorrhoeae","author":"Semchenko","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jvacx.2021.100107_b0120","unstructured":"Sexually Transmitted Infection Vaccines: Opportunities for Development, Research, and Implementation Symposium Report. Vancouver, Canada: Sexually Transmitted Infection Vaccines Consortium (STRIVEBC); 2020. [Available from: https:\/\/www.strivebc.org\/publications-and-resources]."},{"issue":"14","key":"10.1016\/j.jvacx.2021.100107_b0125","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.vaccine.2014.01.053","article-title":"Vaccines against sexually transmitted infections: the way forward","volume":"32","author":"Broutet","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2021.100107_b0130","unstructured":"STI & HIV 2019 World Congress 2019 [Available from: http:\/\/stihiv2019vancouver.com\/]."},{"issue":"2","key":"10.1016\/j.jvacx.2021.100107_b0135","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jvacx.2021.100107_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.jvacx.2021.100107_b0145","series-title":"Weighted average (weighted mean) in A dictionary of statistics","first-page":"456","author":"Upton","year":"2014"},{"key":"10.1016\/j.jvacx.2021.100107_b0150","doi-asserted-by":"crossref","DOI":"10.1071\/SH19060","article-title":"Advancing vaccine development for gonorrhoea and the Global STI Vaccine Roadmap","author":"Gottlieb","year":"2019","journal-title":"Sex Health"},{"key":"10.1016\/j.jvacx.2021.100107_b0155","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3389\/fimmu.2019.02417","article-title":"Progress toward a gonococcal vaccine: the way forward","volume":"10","author":"Russell","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jvacx.2021.100107_b0160","unstructured":"Cg. Study to assess gonorrhoeae immune responses induced by a N. Meningitidis vaccine (4CMenB). Identifier: NCT04094883. Bethesda, MD: National Library of Medicine (US); 2019 [Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04094883?term=bexsero&cond=Gonorrhea&cntry=US&draw=1&rank=1]."},{"key":"10.1016\/j.jvacx.2021.100107_b0165","unstructured":"Koplon S. NIH study to explore vaccine for gonorrhea prevention: UAB News; 23 Oct 2019 [Available from: https:\/\/www.uab.edu\/news\/health\/item\/10852-nih-study-to-explore-vaccine-for-gonorrhea-prevention]."},{"key":"10.1016\/j.jvacx.2021.100107_b0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/d41586-020-03626-1","article-title":"What the lightning-fast quest for COVID vaccines means for other diseases","volume":"589","author":"Ball","year":"2021","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.jvacx.2021.100107_b0175","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.vaccine.2019.05.009","article-title":"Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jvacx.2021.100107_b0180","unstructured":"WHO preferred product characteristics for herpes simplex virus vaccines. Switzerland: World Health Organization; 2019."},{"key":"10.1016\/j.jvacx.2021.100107_b0185","unstructured":"Ten threats to global health in 2019: World Health Organization; 2019."},{"issue":"34","key":"10.1016\/j.jvacx.2021.100107_b0190","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1016\/j.vaccine.2015.04.040","article-title":"Strategies for addressing vaccine hesitancy \u2013 a systematic review","volume":"33","author":"Jarrett","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jvacx.2021.100107_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000270","article-title":"A population-based evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt","volume":"7","author":"Ogilvie","year":"2010","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.jvacx.2021.100107_b0200","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2020-003455","article-title":"Conference equity in global health: a systematic review of factors impacting LMIC representation at global health conferences","volume":"6","author":"Velin","year":"2021","journal-title":"BMJ Glob Health"}],"container-title":["Vaccine: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136221000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590136221000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T02:05:20Z","timestamp":1762913120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590136221000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":40,"alternative-id":["S2590136221000243"],"URL":"https:\/\/doi.org\/10.1016\/j.jvacx.2021.100107","relation":{},"ISSN":["2590-1362"],"issn-type":[{"value":"2590-1362","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Priorities for sexually transmitted infection vaccine research and development: Results from a survey of global leaders and representatives","name":"articletitle","label":"Article Title"},{"value":"Vaccine: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvacx.2021.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}